This Week's Biotech Buzz: FDA Greenlights Key Treatments While Mega-Deals Reshape the Industry

The biotech sector generated significant industry buzz this week as major regulatory wins, high-value acquisitions, and breakthrough clinical data dominated headlines. From groundbreaking FDA approvals to a $7.8 billion acquisition, here’s what shaped the conversation in the biotech world.

FDA Approvals Creating Major Regulatory Buzz

The regulatory environment produced a mixed but predominantly positive week for the sector. Three significant approvals stood out, each addressing different therapeutic needs and generating substantial market interest.

Eton Pharmaceuticals (ETON) received FDA approval for DESMODA (desmopressin acetate) oral solution for central diabetes insipidus—marking the first FDA-approved oral liquid formulation of desmopressin. The company projects the medication could capture peak annual sales of $30-50 million, with availability beginning March 9, 2026. ETON shares closed Thursday trading at $17.25, down 2.27%, reflecting initial market reaction to the approval.

Allurion Technologies (ALUR) secured FDA pre-market approval for its Allurion Gastric Balloon System featuring the swallowable Smart Capsule. The non-surgical device expands in the stomach to create fullness for approximately four months before naturally passing from the body—a significant development in obesity management for patients with BMI between 30-40. ALUR closed Thursday’s session at $1.25, up 1.63%.

Armata Pharmaceuticals (ARMP) achieved a Qualified Infectious Disease Product (QIDP) designation from the FDA for AP-SA02, its bacteriophage-based candidate for complicated Staphylococcus aureus bacteremia including MRSA. The designation unlocks five years of added market exclusivity and makes the candidate eligible for Fast Track status and priority review. ARMP closed trading at $10.83, up 1.88%.

However, not all regulatory news proved positive. MacroGenics (MGNX) faced a setback when the FDA placed a partial clinical hold on its Phase 2 LINNET trial studying Lorigerlimab in gynecologic cancers, following safety events including Grade 4 thrombocytopenia, myocarditis, and neutropenia in four patients. No new enrollment will proceed until the FDA lifts the restriction, though current participants may continue treatment. MGNX closed Thursday’s trading at $1.98, up 3.13%.

Blockbuster Deals and Strategic Partnerships Generate Dealmaking Buzz

The merger and acquisition activity this week demonstrated continued confidence in biotech innovation and cell therapy’s therapeutic potential.

Gilead Sciences (GILD) announced a definitive agreement to acquire Arcellx (ACLX) for $115 per share in cash, plus a $5 per share contingent value right, representing an implied equity value of $7.8 billion. Gilead already owns approximately 11.5% of Arcellx’s outstanding stock. The transaction strengthens Gilead’s cell therapy position through its Kite Pharma subsidiary and enhances the existing collaboration around anitocabtagene autoleucel (anito-cel). GILD closed trading at $143.77, down 2.28%.

Vir Biotechnology (VIR) entered a global strategic collaboration with Astellas Pharma (ALPMF) for VIR-5500, a PSMA-targeting T-cell engager designed for metastatic prostate cancer. Vir will receive $335 million upfront, including $240 million in cash and a $75 million equity investment at 50% premium, plus up to $1.37 billion in future milestones. Astellas will lead U.S. commercialization while Vir retains co-promotion optionality. VIR closed at $9.32, down 6.80%, while ALPMF gained 7.72% to close at $16.05.

Kairos Pharma (KAPA) signed a term sheet to acquire two oncology assets from privately held Celyn Therapeutics: CL-273 (a reversible, wild-type-sparing pan-EGFR inhibitor targeting EGFR-mutated lung cancer) and CL-741 (a Phase 1-ready c-MET kinase inhibitor). The EGFR market alone is valued at $16.2 billion in 2026, with the c-MET inhibitor market projected to exceed $10 billion by 2030. KAPA closed trading at $0.55, down 12.15%.

Clinical Trial Data Fueling Positive Market Sentiment

This week’s clinical trial results demonstrated progress across multiple therapeutic areas, creating considerable buzz about emerging treatment options.

MoonLake Immunotherapeutics (MLTX) reported positive Phase 2 results from its S-OLARIS trial of Sonelokimab in axial spondyloarthritis. At Week 12, 81% of patients achieved an ASAS40 response, with over 80% showing clinically meaningful improvements in disease activity scores. PET imaging revealed significant reductions in inflammation and osteoblast activity in sacroiliac joints—a key factor in preventing irreversible bone fusion. MLTX closed at $17.68, down 2.96%.

Novo Nordisk (NVO) reported positive results from a Chinese Phase 2 trial of UBT251, a triple agonist targeting GLP-1, GIP, and glucagon receptors for obesity management. Patients treated with UBT251 achieved 19.7% weight loss at 24 weeks compared to 2% with placebo among 205 enrolled participants. The company plans to initiate Phase 3 trials in Chinese patients based on these encouraging results. NVO closed Thursday’s trade at $37.52, down 0.27%.

However, Novo Nordisk also experienced a clinical setback when CagriSema (cagrilintide/semaglutide combination) missed its primary non-inferiority endpoint against Lilly’s Zepbound in the REDEFINE 4 trial. CagriSema produced 23% body weight loss versus 25.5% with tirzepatide at 84 weeks, falling short of the statistical threshold for non-inferiority. NVO closed Thursday’s session at $37.62, down 1.42%.

Gossamer Bio (GOSS) announced that seralutinib, an inhaled tyrosine kinase inhibitor for pulmonary arterial hypertension, missed the prespecified alpha threshold in its Phase 3 PROSERA trial. While seralutinib showed a 13.3-meter improvement in six-minute walk distance versus placebo, this fell short of statistical significance. Gossamer plans FDA discussions regarding next steps. GOSS closed trading at $0.40, up 5.76%.

On the positive side, Palvella Therapeutics (PVLA) reported that QTORIN (rapamycin anhydrous gel) met its primary endpoint in the Phase 3 SELVA study for microcystic lymphatic malformations, with a mean improvement of 2.13 points on the mLM-IGA. The company projects submitting a New Drug Application in the second half of 2026. PVLA surged 15.35% to close at $148.34.

Argenx (ARGX) announced that VYVGART met primary goals in the Phase 3 ADAPT OCULUS trial for ocular myasthenia gravis, demonstrating statistically significant improvement in MGII patient-reported outcome scores at Week 4. Patients experienced marked reductions in diplopia and ptosis, with no new safety concerns identified. ARGX closed trading at $771.53, up 5.59%.

AtaiBeckley (ATAI) disclosed positive Phase 2a results for EMP-01 in social anxiety disorder, demonstrating favorable safety and tolerability across 71 participants. While secondary efficacy endpoints showed encouraging signals suggesting symptom reduction, the exploratory findings indicate potential for continued development. ATAI closed at $3.73, down 14.06%.

This week’s convergence of regulatory approvals, strategic partnerships, and clinical breakthroughs demonstrated why the biotech sector continues to generate significant industry buzz among investors and clinicians alike.